Prevalence, Treatment Modalities and Prognosis of Familial Prostate Cancer in a Screened Population

Abstract

Although screened men 55 to 75 years old with a father or a brother having prostate cancer themselves are at a substantially greater risk for the disease, the clinical presentation, treatment modalities and prognosis by biochemical progression are not different compared to sporadic cases.